Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity:Initial SAR and Assessment of In Vivo Activity by Thomas, Michael et al.
                                                                    
University of Dundee
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In
Vitro Antileishmanial Activity
Thomas, Michael; De Rycker, Manu; Wall, Richard J.; Spinks, Daniel; Epemolu, Ola; Manthri,
Sujatha
Published in:








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Thomas, M., De Rycker, M., Wall, R. J., Spinks, D., Epemolu, O., Manthri, S., Norval, S., Osuna-Cabello, M.,
Patterson, S., Riley, J., Simeons, F. R. C., Stojanovski, L., Thomas, J., Thompson, S., Naylor, C., Fiandor, J. M.,
Wyatt, P. G., Marco, M., Wyllie, S., ... Gilbert, I. H. (2020). Identification and Optimization of a Series of 8-
Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo
Activity. Journal of Medicinal Chemistry, 63(17), 9523-9539. https://doi.org/10.1021/acs.jmedchem.0c00705
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Dec. 2021
Identification and Optimization of a Series of 8‑Hydroxy
Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial
SAR and Assessment of In Vivo Activity
Michael G. Thomas,* Manu De Rycker, Richard J. Wall, Daniel Spinks, Ola Epemolu, Sujatha Manthri,
Suzanne Norval, Maria Osuna-Cabello, Stephen Patterson, Jennifer Riley, Frederick R. C. Simeons,
Laste Stojanovski, John Thomas, Stephen Thompson, Claire Naylor, Jose M. Fiandor, Paul G. Wyatt,
Maria Marco, Susan Wyllie, Kevin D. Read, Timothy J. Miles,* and Ian H. Gilbert*
Cite This: J. Med. Chem. 2020, 63, 9523−9539 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000−65 000 deaths annually. The
available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options. The need for new
treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline
(GSK), and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point, and an early compound
demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the
development of compounds with improved in vitro profiles, but these were poorly tolerated in vivo. Investigation of the mode of
action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to
drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for
phenotypically active series.
■ INTRODUCTION
According to the World Health Organization (WHO),
neglected tropical diseases (NTDs) affect in excess of 1 billion
people, the majority being in the most impoverished areas of the
world.1 Of these NTDs, visceral leishmaniasis (VL) remains one
of the most challenging to treat. VL is caused by infection with
the protozoan parasites Leishmania donovani and Leishmania
infantum, which are transmitted through the bite of female
phlebotomine sand flies.2 Following infection, parasites reside
predominantly in the liver, spleen, and bone marrow, and if left
untreated, the disease is invariably fatal. Although it is
challenging to precisely determine the number of people
affected by VL, WHO estimates suggest that 50 000−90 000
new infections result in an annual death toll of between 26 000
and 65 000, with the vast majority of cases occurring in India,
Bangladesh, Sudan, Ethiopia, and Brazil.3
Although there are a number of available treatments, all suffer
frommajor issues that limit their use. Miltefosine, the only orally
available treatment, is teratogenic so can only be prescribed to
women of childbearing age alongside contraception, and also
shows other side effects, as well as variable efficacy.4 Liposomal
amphotericin B (Ambisome) is widely effective in Asia, but its
use is limited by the need for intravenous (iv) administration
which requires hospitalization, and it also requires a cold-chain
for storage. An alternative aminoglycoside antibiotic paromo-
mycin is much less expensive but demonstrates variable efficacy
and requires a long course of painful intramuscular injections.5
Finally, pentavalent antimonials, such as sodium stibogluconate,
have been widely used since the 1940s, but they are cardiotoxic,
require parenteral administration, and are largely ineffective in
large areas of India due to high levels of drug resistance.
Although new compounds have recently entered the develop-
ment pipeline,6 including two preclinical candidates developed
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within this collaboration (DDD853651/GSK3186899 and
DDD1305143/GSK3494245) as well as the Novartis com-
pound GNF6702, which have been disclosed in recent
publications,7 there is still an urgent need for new treatments
with improved safety profiles, more straightforward admin-
istration, lower costs, and also with alternate modes of action.
One of the major challenges for drug discovery for VL is the
lack of robustly validated drug targets in Leishmania spp. For this
reason, to identify suitable start points for drug discovery,
compound libraries are screened directly against parasites in
vitro, leading to phenotypically active compounds with unknown
mechanisms of action. An additional confounding factor in
attempts to identify chemical start points is the fact that in the
human host, parasites are foundwithinmacrophages, where they
reside within a parasitophorous vacuole. Therefore, relevant
high-content screens, suitable for high-throughput screening
(HTS), require culture of parasites in macrophages, typically
differentiated THP-1 cells.8 For any compounds to be identified
as hits in these screens, they would be required to have suitable
physicochemical properties to cross a number of cell
membranes, across various pH gradients, as well as having
antiparasitic activity. As a result, hit rates are extremely low in
these assays, typically below 0.1%.9 Nevertheless, compound
series that are active in this assay and can be developed to give
suitable properties for in vivo dosing have a high likelihood of
success in rodent models of VL.
Using this intramacrophage assay, an HTS screen of a
GlaxoSmithKline (GSK) collection of 1.8 M compounds was
performed against L. donovani.10 The hits identified were
screened in secondary antiparasitic assays, assessed for non-
specific cytotoxicity in HepG2 cells, clustered, and filtered based
on favorable physicochemical properties, resulting in the
identification of 33 chemical series and 75 singletons. One of
the identified series was exemplified by 1 (Table 1), an 8-
hydroxynaphthyridine, which was shown to have potency
against the parasite (pEC50 = 6.5) with ∼100-fold selectivity
over the human THP-1 cell line (pEC50 = 4.5). This compared
favorably to the current treatments, amphotericin (pEC50 = 6.7)
and miltefosine (pEC50 = 5.4). Upon further profiling, 1 was
shown to have reasonable aqueous (aq) solubility (219 μM) but
low stability in mouse liver microsomes (Cli = 18 mL/min/g).
On the basis of this, 1 was selected as a suitable start point for a
hit-to-lead program.
The principal aim of this work was to identify analogues of 1
with a suitable profile for dosing in a mouse efficacy model of VL
as rapidly as possible, to demonstrate that the series had the
potential to progress into lead-optimization. Therefore, the
initial chemistry program focused on understanding the
structure−activity relationship (SAR) of the series, with an
aim of identifying compounds with improved solubility and
metabolic stability, as well as suitable potency for in vivo studies.
Our targets were to achieve pEC50 > 5.8, aqueous solubility >200
μM, and mouse liver microsomal clearance of <5.0 mL/min/g,
as these criteria had been used previously to identify chemical
series likely to have in vivo efficacy.12
■ RESULTS AND DISCUSSION
Lack of knowledge regarding the molecular target of compound
1 made optimization challenging, with no guide as to the
potential pharmacophore, or which vectors were most likely to
positively influence activity. We therefore focused on utilizing
tractable chemistry that would facilitate a rapid exploration of
SAR. Also, to maintain good solubility and hopefully improve
metabolic stability, we aimed to reduce, or at least maintain, the
LogD of the initial analogues. This led us to focus on the triazole
substituent, as well as the 5-position of the naphthyridine as
initial points for exploration.
SAR of 7-Triazolyl Analogues. Variations to the benzyl
substituent of the triazole (Table 2), including substitutions on
the phenyl position (exemplified by 2), or on the methylene
(exemplified by 3), led to a ∼10-fold loss in potency compared
to 1, although 3 did show an improvement in metabolic stability.
A truncated analogue 4 was inactive, but we were encouraged by
its improved solubility and metabolic stability. We thus replaced
the 4-chlorophenyl group of 1withmore polar substituents, with
the aim of regaining in vitro potency while maintaining a
favorable absorption, distribution, metabolism, and excretion
(ADME) profile. Morpholine-substituted 5 and pyrrolidinone-
substituted 6 were synthesized and indeed proved to be both
soluble and metabolically stable, although both compounds
were essentially inactive. Switching to an amide as an isosteric
replacement for the triazole was also investigated, and the
matched pairs (7 vs 1) showed similar levels of potency,
although the amide did not appear to show any clear advantage
over the triazole as its mouse liver microsomal clearance was still
not below the targeted 5 mL/min/g.
Table 1
aLd InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes. Data are the result of at least four independent
replicates, and standard deviations are ≤0.4. bCli is mouse liver microsomal intrinsic clearance.
cAq solubility is kinetic aqueous solubility. dND
means not determined.
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We next switched attention to the naphthyridyl 5-position.
Initially, nitrogen-linked analogues were investigated. While
both methylamine 8 and dimethylamine 9 were essentially
inactive, larger amines such as p-chlorobenzylamine 10 and
morpholine 11 both had pEC50 values above 5, with good
solubility and low clearance. Cyclic amides, such as 12, proved to
be inactive, as did sultam 13, presumably due to the reduced
electron density in the aromatic ring. Compound 13 was of
particular interest as 5-sultam-substituted naphthyridines had
been previously reported in a series of integrase inhibitors and
were shown to impart very good pharmacokinetics (PK)
properties.13 Indeed, the lead compound from this series
progressed as far as phase II clinical trials (compound 30;
Table 5). Further exploration of N-linked analogues failed to
deliver compounds with the necessary potency for progression
to in vivo studies, so we switched our focus to carbon-linked
analogues. Interestingly, the unsubstituted phenyl analogue 14
showed reasonable potency (pEC50 = 5.9), and further
analogues showed ortho-substitution to be beneficial, with the
o-trifluoromethyl analogue 15 giving a significant increase in
antiparasitic activity (pEC50 = 7.0), possibly driven by the
increased lipophilicity, and the o-methoxy analogue 16 showing
a good balance of potency, stability, and solubility (pEC50 = 6.2,
Cli = 1.4 mL/min/g and aqueous solubility >250 μM).
Replacement of phenyl by aromatic heterocycles (such as
pyridyl or pyrazolyl) was also explored, as was substitution on
the other side of the naphthyridine (2-, 3-, and 4-positions), but
these changes led to only weakly active compounds (data not
shown).
Profiling of Compound 16. Compounds 15 and 16 both
showed a promising balance of potency, solubility, and
metabolic stability. Because of having higher metabolic stability
(in mouse liver microsomes) and lower Chrom Log D,
compound 16 was progressed into a VL in vivo efficacy study,
carried out in our previously described VL mouse model.7 Mice
were dosed orally with the standard antileishmanial drug
miltefosine, or with 16 dosed intraperitoneal (ip) two times
daily for 5 days post infection (although 16 had a suitable profile
for oral dosing, we elected to dose ip to maximize exposure and
increase our chances of demonstrating in vivo proof of concept
for the series). Parasite load was determined in the livers of
animals 3 days after cessation of treatment, and parasite burden
was expressed in Leishman Donovan units (LDUs, the mean
number of amastigotes per liver cell × mg weight of liver). The
blood exposure of compound 16 was also determined in dosed
animals on days 1 and 5 to better understand the PK/
pharmacodynamics (PD) relationship of the series. According
to our project criteria, a compound needs to reduce parasite
burden by >70% before being considered suitable for
progression to lead-optimization, while a reduction of >95%
would be considered suitable for a preclinical development
candidate.12
In the study, miltefosine behaved as expected, reducing
parasite levels by >99% at 30 mg/kg qd. After twice daily ip
dosing at 50 mg/kg, compound 16 reduced parasite burden in
mouse liver by 46%. This provided an early proof of concept for
this series but fell short of our target of >70% parasite reduction.
Upon examining the blood samples taken on days 1 and 5, it was
clear that 16 was rapidly cleared from blood, with unbound
concentrations of compound exceeding EC99 only during the
first hour post-dose (Table 3). Further examination of the
samples revealed the presence of glucuronidated adducts of 16,
suggesting secondary metabolism as the key driver of the low
exposure.
Glucuronidation is a means of increasing water solubility of
small molecules, facilitating their elimination from the body in
urine. It involves transfer of the glucuronic acid component of
uridine diphosphate glucuronic acid to a suitable substrate,
catalyzed by UDP-glucuronosyltransferase (UGT), and occurs
mainly in the liver.14 Glucuronidation occurs at nucleophilic
sites such as R−OH, R−NH2, or R−COOH, which can be
present in the small molecule, or generated via phase I
metabolism. Due to the low rates of microsomal clearance of
16, alongside our in vivo data, we surmised that glucuronidation
was occurring on the parent compound, most likely at the
phenolic OH or the triazole N−H. Also, the observed reduction
of parasite load, despite the high in vivo clearance, suggested that
reducing glucuronidation to increase the duration of exposure
above EC99 would be a key strategy to progress the series toward
lead-optimization.
As a means of measuring glucuronidation in vitro, 16 was
assessed in a mouse liver hepatocyte assay. Unfortunately, 16
showed similar stability to that seen in mouse liver microsomes
(0.9 mL/min/g inmicrosomes vs 1.4mL/min/g in hepatocytes)
with negligible amounts of the glucuronide adduct being
observed. This suggested that there was little involvement of
the hepatic UDP-glucuronosyltransferase in the in vivo phase II
metabolism. This result made series progression challenging, as
there was no way to determine the potential impact of
glucuronidation without running an in vivo study, limiting our
understanding of the SAR surrounding the observed secondary
metabolism.
One possible strategy to identify compounds with improved
metabolic stability would be to reduce lipophilicity. This had
been shown previously to be a potential strategy for reducing
glucuronidation;15 however, as shown in Figure 1, this was very
challenging within this compound series. Looking at measured
log D (Chrom Log D7.4),
11 analogues with Chrom Log D7.4
values below 3 were generally only weakly active, with pEC50’s
above 5.8 only being achieved where Chrom LogD7.4 was
greater than 3. In our experience, this is a common problem
when trying to optimize series phenotypically, where increasing
potency without increasing lipophilicity is very challenging; this
highlights a key advantage of running structure-enabled
programs. Because of this, alternative approaches to improving
metabolic stability were required.
Table 2. continued
aLd InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes. Data are the result of at least three independent
replicates, and standard deviations are ≤0.4. bCli is mouse liver microsomal intrinsic clearance. cAq solubility is kinetic aqueous solubility. dND
means not determined.
Table 3. Blood Levels of 16, Measured on Days 1 and 5 of a
Mouse Efficacy Study, Dosing ip at 50 mg/kg b.i.d.
AUC(0−t) (μM min) Cmax (μM) Tmax (h)
day 1 day 5 day 1 day 5 day 1 day 5
1236 606 25.2 4.2 0.5 0.5
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SAR of the Naphthyridine Core. Our initial approach to
reduce potential phase II metabolism within the series was
therefore to investigate the SAR around the phenolic hydroxyl
group and the triazole. Understanding which of these features
was important for antiparasitic activity might enable us to
synthesize potent analogues with lower potential for glucur-
onidation. As shown in Table 4, removal or methylation of the
naphthyridine 8-hydroxyl group led to a loss of antiparasitic
activity compared to 16 (17 and 18, respectively), although 18
was close to the targeted pEC50 of 5.8. Also, replacement of
triazole with oxadiazole to remove the nucleophilic N−H led to
a loss of activity (19). Synthesis of other analogues to explore the
naphthyridine SAR proved extremely challenging within the
triazole subseries, so to more rapidly address this, we switched
attention to the bioisosteric replacement of triazole with amide;
this change had previously been seen to have limited effect on
potency (e.g., 1 vs 7) and allowed much more straightforward
synthesis of the analogues of interest. Thus, deletion of the
naphthyridine N-6 of 7 led to a compound that was toxic to the
host THP-1 cells, and deletion of naphthyridine N-1 led to loss
of antiparasitic activity (20 and 21, respectively). Moving to a
scaffold that trapped the phenolic OH as a carbonyl removed all
antiparasitic activity despite the parent amides having pEC50
values >6.0 (comparing 22 to 28 and 23 to 27). Finally, we
examined Raltegravir (24), an inhibitor of human immunode-
ficiency virus (HIV) integrase marketed as a treatment for
HIV.16 As shown in Figure 2, 24 contains the key acceptor−
donor−acceptor binding motif identified within the naphthyr-
idine series. Although 24 was inactive in our in vitro Leishmania
assays, we surmised that transferring the known SAR of the
naphthyridine core onto the Raltegravir scaffold could be a
viable strategy to regain activity. Unfortunately, as exemplified
by 25, none of the analogues based on this scaffold were active.
From this round of synthesis, we concluded that we were
unlikely to identify active compounds without the acceptor−
donor−acceptor binding motif of the 7-substituted-1,6-naph-
thyridin-8-ol core.
SAR of 7-Carboxamide Analogues. Previous SAR
demonstrated that replacing the triazole with an amide led to
compounds such as 7 that retained antiparasitic activity. Since 7
itself was metabolically unstable (Cli = 10 mg/mL/g), we
became interested in transferring the SAR from the triazole
subseries (e.g., 16) to investigate its impact on metabolic
stability, with a particular focus on glucuronidation. To this end,
we synthesized 26 (Table 5) as a direct analogue of triazole 16.
Although it did not show sufficient potency for progression into
efficacy studies, it had reasonable aqueous solubility (219 μM)
and good metabolic stability (Cli = 0.9 mL/min/g) and was
therefore progressed into a mouse PK study to assess the extent
of in vivo glucuronidation. After dosing (50 mg/kg ip) and
analyzing the metabolites generated (Figure 3), there was little
evidence of glucuronidation, with the major metabolism
observed being hydroxylation. As significant quantities of parent
were still present 8 h post-dose, this supported a strategy of
switching to the amide series to reduce phase II metabolism and
improve in vivo exposure.
With this in mind, we further explored the SAR of the amide
subseries, as shown in Table 5. We synthesized a set of benzyl
amides, where 4-methoxy analogue 27 and α-methyl-4-fluoro
analogue 28 both gave very encouraging profiles, meeting
progression criteria in terms of potency, metabolic stability, and
clearance. Alternatively, nonaromatic amides were explored, and
although none were identified with suitable profiles for
progression, cyclopropylmethyl analogue 29 did demonstrate
reasonable potency. Due to its impressive in vitro potency, we
selected 28 for progression into an in vivo PK study. However,
upon dosing (50 mg/kg ip), the compound proved to be toxic,
rapidly giving symptoms (within 3.5 h) requiring termination of
the experiment.
We noted that a related compound from Merck, L-870,810
(30),17 was reported as a clinical candidate targeting HIV
integrase, which progressed as far as phase II clinical trials.
Compound 30 was inactive in our in vitro efficacy assays, but the
report, alongside the in vivo data for 26, suggested that
compounds with substitutions in the naphthyridine 5-position
could have suitable profiles for in vivo studies. Also, introducing
substituents into the 5-naphthyridyl position had been a
successful strategy for improvingmetabolic stability and potency
in the triazole subseries. We therefore investigated a range of 5-
substituted naphthyridyl analogues (Table 5). THP-amine 31
and morpholine 32 lost potency compared to parent compound
7, so we switched attention back to 5-phenylnaphthyridines.
Previously identified groups were combined (the 4-methox-
yphenyl of 16 and the cyclopropylmethyl amide of 29), leading
to 33, which unfortunately did not deliver the expected increase
in potency. Further combinations of nonaromatic amides with
differently substituted 5-phenylnaphthyridines were synthe-
sized, and while changing the phenyl substituent gave flat SAR
and no advantage over previous compounds, exploration of the
amide led to 34 with a trans-4-methoxycyclopropylamide.
Compound 34 gave a good balance of potency, solubility, and
microsomal stability and was therefore selected for a mouse PK
study. Disappointingly, when dosed at 50 mg/kg ip, the mice
again displayed the similar symptoms as with compound 28, and
the study was terminated after 60 min.
Profiling of 16, 28, and 34.Due to the encouraging results
within the series (16 showing low-level efficacy and 26 giving a
good PK profile), we were keen to understand the origins of the
observed toxicity of 28 and 34. As previously mentioned,
compound 30 progressed as far as phase II clinical trials as an
HIV integrase inhibitor, and although it was inactive against VL,
we were keen to assess whether there was scope to progress our
related series further. To this end, two studies were conducted in
parallel; a screen against receptors with known links to toxicity
and investigation of mode of action (MoA).
First, the compounds which were poorly tolerated in mice, 28
and 34, were screened against a panel of >30 receptors with
Figure 1. Chrom LogD7.4 vs intramacrophage potency (Ld InMac
pEC50) for all compounds presented. The green line represents
Chrom LogD7.4 = 3; the black line represents Ld InMac pEC50 = 5.8.
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known links to in vivo toxicity (GSK-enhanced cross-screen
panel (eXP)).18 Compound 28 gave a pIC50 value of 5.4 against
monoamine oxidase A, highlighting a slight risk of drug−drug
interactions and possible side effects, and a pIC50 value of 4.9 in a
phenotypic cell health assay, suggesting possible effects on
mitochondrial integrity that could lead to an increased risk of
Table 4
aLd InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes. Data are the result of at least three independent
replicates, and standard deviations are ≤0.4. bCli is mouse liver microsomal intrinsic clearance. cAq solubility is kinetic aqueous solubility. dND
means not determined.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
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hepatotoxicity. Compound 34 also showed potency in the cell
health assay, alongside activity in a bile salt export pump (BSEP)
assay (pIC50 value of 4.8, hepatotoxicity risk) and a
phospholipidosis assay. From this, it was not clear whether the
effects seen in the receptor screen were related to the observed in
vivo toxicity.
Alongside these screens, mode-of-action studies were initiated
focusing on 10, 16, and 28, as representatives of both the triazole
and amide subseries. We were particularly interested in
confirming that the compounds inhibited a shared target,
identifying off-target effects, and understanding the source of the
observed toxicity. The results of these studies have been
reported previously and demonstrated that the compounds act
as nonspecific chelators of divalent metal cations, in particular
Zn2+, Fe2+, and Cu2+, and that this property is likely responsible
for their antiparasitic activity.19 Indeed, the propensity of these
compounds to nonspecifically chelate divalent cations may well
explain the observed in vivo toxicity associated with this series.
Figure 2.Highlighting the acceptor−donor−acceptor motifs of triazole
analogue 1, amide analogue 7, and Raltegravir 24.
Table 5
aLd InMac is the intramacrophage assay carried out in THP-1 cells with L. donovani amastigotes. Data are the result of at least three independent
replicates, and standard deviations are ≤0.4. bCli is mouse liver microsomal intrinsic clearance. cAq solubility is kinetic aqueous solubility. dND
means not determined.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00705
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Chemistry. To access the required analogues, a number of
different approaches were needed, as illustrated in scheme 1−3.
Compounds 1 and 2 were previously reported,20 and synthesis
of the remaining 7-triazolyl-8-hydroxy naphthyridines started
from 7-cyanonaphthyridine 3520 (Scheme 1), where cyclization
with substituted hydrazides under acidic conditions led to
compounds 3−6. To access 5-substituted analogues, 35 could
be brominated withN-bromosuccinimide (NBS) to give 36 and
subsequently cyclized to give 37, which was treated with a
suitable amine to give 8−11. For 12 and 13, protection of the
phenol proved to be necessary. Hence, 36 could be tosyl-
protected to give 38, followed by either Buchwald−Hartwig
coupling to introduce the pryrrolidinone (12) or copper
coupling with 1,2-thiazinane 1,1-dioxide to introduce the sultam
(13). Alternatively, 36 could be directly coupled with phenyl-
boronic acid to give 14, or benzyl-protected to give 39, which
could be coupled to give 15 and 16.
To fully explore the SAR around the naphthyridine ring, and
also to introduce alternative heterocycles to replace the triazole,
a number of analogues required bespoke synthesis. Analogues
17, 18, 20, and 21 were synthesized according to established
procedures and are described in the Supporting Information,
with the synthesis of 19, 22, 23, and 25 highlighted in Scheme 2.
Thus, 5-bromo-8-methoxy-1,6-naphthyridine-7-carboxylic acid
40 was cyclized with acetylhydrazide to give 41, followed by
Suzuki coupling and deprotection of the 8-methoxy group to
give oxadiazole 19. Compound 22 was synthesized from 3-
chloropicolinic acid via conversion to the acid chloride,
condensation with ethyl 3-(dimethylamino)acrylate, cyclization
with methylamine, and ester hydrolysis to give 42. This was then
coupled with 4-fluoro-α-(R)-methylbenzylamine to give 22. To
access 23, methyl 3-fluoropicolinate was condensed with tert-
butyl acetate to give 43, which was treated with 4-
acetamidobenzenesulfonyl azide (ABSA), PBu3, then 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU)/iodomethane to give
cyclized 44, which was subsequently hydrolyzed and coupled
with 4-methoxybenzylamine to give 23. Finally, 25 was
synthesized according to a previously published route such
that 2-cyanoanisole was treated with N-methylhydroxylamine
and cyclized to 45. Thermal rearrangement gave 46, which was
treated with 4-fluoro-α-(R)-methylbenzylamine to give 25.21
7-Carboxamide analogues were synthesized from the
corresponding ester 47 according to Scheme 3. Amides 7 and
27−29 were synthesized directly from the ester by treating with
Figure 3. PK profile of 26, showing levels of parent, glucuronide adduct,
major hydroxylated metabolite, and other minor metabolites. Data are
based on two replicates, with error bars representing the range of the
data from the two runs. Blood/water (30 μL, 1:2) were collected
following 50 mg/kg ip administration to Balb Cmice at prescribed time
points; 90 μL of acetonitrile (ACN) was then added to each sample and
the samples were centrifuged for 5 min at 7000 rpm; 90 μL of
supernatant was removed and added to 50 μL of Milli-Q water before
ultrahigh-performance liquid chromatography−quadrupole time-of-
flight (UPLC Q-TOF) analysis.
Scheme 1
aReagents and conditions: (a) 1,4-dioxane/acetic acid, 140−200 °C, 22−38%; (b) NBS, dichloromethane (DCM), 2 h, 84%; (c) acetohydrazide,
1,4-dioxane/acetic acid, 200 °C, 30 min, 45%; (d) relevant amine, N,N-diisopropylethylamine (DIPEA), N-methyl-2-pyrrolidone (NMP), 180 °C,
1−18 h, 25−50%; (e) TsCl, NEt3, DCM, 40 °C, 3 h, 83%; (f) i. for 12: pyrrolidin-2-one, Cs2CO3, Pd(OAc)2, Xantphos, 1,4-dioxane, 65 °C. For
13: 1,2-thiazinane 1,1-dioxide, Cs2CO3, Pd2(dba)3, Xantphos, 1,4-dioxane, 65 °C. ii. NaOMe, dimethylformamide (DMF), 50 °C. iii.
Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 2 h, 7−16% over three steps; (g) BnBr, PPH3, diisopropyl azodicarboxylate (DIAD),
tetrahydrofuran (THF), 0 °C, 18 h, 15%; (h) phenylboronic acid, K3PO4, Pd(dppf)Cl2·CH2Cl2, DMF/water, 130 °C, then acetohydrazide, 1,4-
dioxane/acetic acid, 200 °C, 45 min, 3% over two steps (14); (i) i. relevant boronic acid, K3PO4, tetrakis, 1,4-dioxane/water, 120 °C, 1.5 h. ii.
Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 18 h, 22% (15)/24% (16) over two steps.
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the relevant amine at high temperature. To access the desired 6-
functionalized analogues, 47 was brominated with NBS to give
48, tosyl-protected to give 49, and converted to sultam 30.22
Alternatively, 48 could be treated with 4-chlorobenzylamine to
give 51a, then coupled with another amine to give 31 and 32.
Compound 49 could also be coupled with 2-methoxyphenylbor-
onic acid and hydrolyzed to give 50, which was coupled with
trans-4-methoxycyclohexylamine to give 34. Alternatively, 48
could be treated directly with a relevant amine to give 51b and
51c, with subsequent Suzuki coupling with 2-methoxyphenyl-
boronic acid giving 26 and 33.
■ CONCLUSIONS
To identify new compound series with the potential to be
developed as new therapeutics for VL, a collection of 1.8 M
compounds from the GSK corporate collection was screened
against L. donovani in vitro. One hit series identified from this,
exemplified by 1, was selected for a hit-to-lead program. In vivo
studies of an early compound, 16, demonstrated that the series
had the potential to reduce parasite burden, but that
glucuronidation was a potential barrier to series progression.
Scaffold hopping from the core triazole to an amide was a key
strategy for progressing the series, leading to 28with a very good
in vitro profile. Dosing of 28 identified an issue with toxicity for
the series and further chemistry failed to identify compounds
that did not carry this liability. MoA studies suggested that the
antiparasitic activity, and the toxicity, was likely driven by
chelation of divalent metal cations. Based on these findings, we
concluded that attempting to develop compounds within this
series that would separate antiparasitic activity from inherent
toxicity would be extremely challenging and unlikely to succeed.
With this in mind, work on the series was halted. This
demonstrates the importance of understanding the mode of
action from a very early stage in the drug discovery process,
when working to progress phenotypically active hit compounds.
■ EXPERIMENTAL SECTION
Chemistry. Chemicals and solvents were purchased from Aldrich
Chemical Company, Fluka, ABCR, VWR, AcrosOrganics, Fluorochem,
and Alfa Aesar and were used as received. Air- and moisture-sensitive
reactions were carried out under an inert atmosphere of argon in oven-
dried glassware. Analytical thin-layer chromatography (TLC) was
performed on precoated TLC plates (layer 0.20 mm silica gel 60 with
fluorescent indicator UV254, from Merck). Developed plates were air-
dried and analyzed under a UV lamp (UV254/365 nm). Flash column
chromatography was performed using prepacked silica gel cartridges
(230−400 mesh, 40−63 μm, from SiliCycle) using a Teledyne ISCO
CombiFlash Companion, or CombiFlash Retrieve. 1H NMR and 13C
NMR spectra were recorded on a Bruker Avance DPX 500
spectrometer (1H at 500.1 MHz, 13C at 125.8 MHz). Chemical shifts
(δ) are expressed in parts per million (ppm) recorded using the residual
solvent as the internal reference in all cases. Signal splitting patterns are
described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet
(m), broad (b), or a combination thereof. Coupling constants (J) are
quoted to the nearest 0.1 Hz. Liquid chromatography−mass
spectrometry (LC−MS) analyses were performed with either an
Agilent HPLC 1100 series connected to a Bruker DaltonicsMicrOTOF
or an Agilent Technologies 1200 series HPLC connected to an Agilent
Technologies 6130 quadrupole LC/MS, where both instruments were
connected to an Agilent diode array detector. Mobile phase was water/
acetonitrile + 0.1% HCOOH, or water/acetonitrile + 0.1% NH3; linear
gradient, 80:20−5:95 over 3.5 min and then held for 1.5 min; flow rate,
0.5 mL/min. All intermediates had a measured purity ≥90%, and all
assay compounds had a measured purity of ≥95%, as determined using
this analytical LC−MS system (total ion current (TIC) andUV). High-
resolution electrospray measurements were performed on a Bruker
Scheme 2
aReagents and conditions: (a) i. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), DIPEA, hydroxybenzotriazole (HOBt), acethydrazide,
DCM, 0 °C, 18 h. ii. PPh3, CCl4, NEt3, MeCN, 60 °C, 2 h, 53%. (b) i. Phenylboronic acid, Na2CO3, tetrakis, 1,4-dioxane/water, 120 °C, 18 h. ii.
Trimethylchlorosilane, NaI, MeCN, reflux, 18 h, 44% over two steps; (c) i. oxalyl chloride, DCM, RT then 3-ethoxy-3-oxo-propanoic acid, BuLi,
−78 °C, 1 h. ii. DMF·dimethylacetamide (DMA), DMF, 100 °C, 1 h. iii. MeNH2, ether/EtOH, RT, 1 h. iv. 1 M NaOH, MeOH, RT, 2 h, 69% over
four steps; (d) DIPEA, T3P, DMF, 2 h, 8%; (e) lithium diisopropylamide (LDA), tert-butyl acetate, THF, −78 °C, 2 h, quant. (f) i. ABSA, NEt3,
MeCN, 0 °C, 18 h. ii. PBu3, THF, RT, 15 min. iii. DBU, MeI, MeCN, RT, 18 h, 32% over three steps. (g) i. Trifluoroacetyl (TFA), DCM, RT, 18
h. ii. EDCI, HOBt, DIPEA, DCM, 16 h, 88% over two steps. (h) i. MeNH−OH, Na2CO3, water/EtOH, 28 h, 80 °C. ii. Diethyl
acetylenedicarboxylate, EtOH, RT, 1 h, 61% over two steps. (i) p-Xylene, reflux, 2 days, 41%; (j) toluene, reflux, 18 h, 46%.
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Daltonics MicrOTOF mass spectrometer. Microwave-assisted chem-
istry was performed using a Biotage Initiator Microwave Synthesizer.
7-(3-(Hydroxy(phenyl)methyl)-1H-1,2,4-triazol-5-yl)-1,6-
naphthyridin-8-ol (3). 35 (100 mg, 0.58 mmol) and 2-hydroxy-2-
phenylacetohydrazide (288 mg, 1.74 mmol) in 1,4-dioxane (1.5 mL)/
acetic acid (0.5 mL) were heated in microwave at 140 °C for 2 h. The
mixture was cooled to RT, and the resulting solid was collected, washed
with 1,4-dioxane, and dried under vacuum to give 3 (43 mg, 0.13 mmol,
22%). 1H NMR (dimethyl sulfoxide (DMSO)-d6): δ 14.90 (s, 1H),
12.29 (bs, 1H), 9.15 (s, 1H), 9.02 (s, 1H), 8.63−8.56 (m, 1H), 7.82−
7.74 (m, 1H), 7.56−7.50 (m, 2H), 7.42−7.24 (m, 3H), 6.23 (bs, 1H),
5.91 (bs, 1H); m/z [M + H]+ calcd for C17H14N5O2, 320.1147; found,
320.1146.
7-(3-Methyl-1H-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (4).
35 (30 mg, 0.16 mmol) and acetylhydrazide (58.4 mg, 0.79 mmol) in
1,4-dioxane (2 mL)/acetic acid (0.2 mL) were heated in microwave at
200 °C for 15min. Themixture was cooled, solvent-evaporated, and the
crude material was purified by mass-directed prep. HPLC to give 4 (10
mg, 0.04 mmol, 27%). 1HNMR (DMSO-d6): δ 14.74 (s, 1H), 12.45 (s,
1H), 9.18−9.15 (m, 1H), 9.04 (s, 1H), 8.63−8.58 (m, 1H), 7.83−7.76
(m, 1H), 2.45 (s, 3H); 13C NMR (DMSO-d6): δ 158.8, 158.5, 154.5,
149.5, 143.9, 141.9, 136.7, 125.6, 124.8, 12.8; m/z [M + H]+ calcd for
C11H10N5O, 228.0885; found, 228.0886.
7-(3-(Morpholinomethyl)-1H-1,2,4-triazol-5-yl)-1,6-naph-
thyridin-8-ol (5). 35 (150 mg, 0.88 mmol) and 2-(4-morpholinyl)-
acetohydrazide (419mg, 2.63mmol) in 1,4-dioxane (3mL)/acetic acid
(0.3 mL) were heated in microwave at 180 °C for 2 h. The resulting
solution was evaporated, cyclohexane (3 × 10 mL) was added, and
evaporated. Acetone (15 mL) was added, and the resulting solid was
collected by filtration, washedwithMeOH, and dried to give 5 (105mg,
0.34 mmol, 38%). 1H NMR (DMSO-d6): δ 14.83 (s, 1H), 9.18−9.16
(m, 1H), 9.04 (s, 1H), 8.63−8.60 (m, 1H), 8.15 (s, 1H), 7.82−7.78 (m,
1H), 3.73 (s, 2H), 3.63−3.58 (m, 4H), 2.60−2.54 (m, 4H, under
solvent peak); m/z [M + H]+ calcd for C15H17N6O2, 313.1413; found,
313.1411.
1-((5-(8-Hydroxy-1,6-naphthyridin-7-yl)-1H-1,2,4-triazol-3-
yl)methyl)pyrrolidin-2-one (6). 6 was synthesized by an analogous
method to 3, from 35 (100 mg, 0.58 mmol) and 2-(2-oxopyrrolidin-1-
yl)acetylhydrazide (273 mg, 1.74 mmol). The crude material was
purified by mass-directed prep. HPLC to give 6 (70 mg, 0.15 mmol,
26%). 1HNMR (DMSO-d6): δ 9.20−9.17 (m, 1H), 9.06 (s, 1H), 8.65−
8.61 (m, 1H), 7.83−7.80 (m, 1H), 4.61 (s, 2H), 3.47−3.44 (m, 2H),
2.34−2.29 (m, 2H), 2.04−1.95 (m, 2H); m/z [M + H]+ calcd for
C15H15N6O2, 311.1256; found, 311.1260.
N-(4-Chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carbox-
amide (7). A mixture of 47 (51 mg, 0.25 mmol) and 4-chlorobenzyl-
amine (701 mg, 0.5 mmol) in EtOH (4 mL) was stirred at 80 °C for 18
h. The hot reaction mixture was poured into a solution of acetic acid
(0.5 mL) in water (4 mL). After stirring for 10 min, cold water (15 mL)
was added and stirred at RT for 40 min. The resulting solid was
collected, washed with water, and dried to give 7 (42 mg, 0.13 mmol,
53%). 1HNMR (DMSO-d6): δ 13.67 (s, 1H), 9.18−9.16 (m, 1H), 8.93
Scheme 3
aReagents and conditions: (a) i. EtOH, reflux, 18 h, 65%; (b) NBS, DCM, room temperature (RT), 2 h, 93%; (c) TsCl, NEt3, DCM, 40 °C, 2 days,
49%; (d) i. 1,2-thiazinane 1,1-dioxide, Cs2CO3, Pd2(dba)3, Xantphos, 1,4-dioxane, 65 °C, 24 h. ii. NaOMe, DMF, 50 °C, 24 h. iii. 4-
Fluorobenzylamine, T3P, DIPEA, DMF, RT, 18 h, 11% over three steps; (e) relevant amine, EtOH, 100 °C, 18 h, 45−86%; (f) (2-
methoxyphenyl)boronic acid, K3PO4, Pd(dppf)Cl2·DCM, 1,4-dioxane/water, 140 °C, 1 h, 30% (26)/38% (33); (g) relevant amine, DIPEA, NMP,
150−180 °C, 5 h, 17% (31)/33% (32); (h) i. (2-methoxyphenyl)boronic acid, tetrakis, Na2CO3, 1,4-dioxane/water, 60 °C, 18 h. ii. NaOMe,
MeOH, 50 °C, 15 min. iii. LiOH, water, 60 °C, 18 h, 58% over three steps; (i) trans-4-methoxycyclohexanamine, DIPEA, T3P, 50 °C, 18 h, 56%.
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(bs, 1H), 8.61 (d, J = 7.7 Hz, 1H), 7.86−7.82 (m, 1H), 7.44−7.39 (m,
4H), 4.55 (d, J = 6.5 Hz, 2H). 13C NMR (DMSO-d6): δ 170.1, 154.6,
142.6, 138.4, 136.5, 132.0, 129.9, 128.8, 127.0, 126.0, 125.4, 42.1; m/z
[M + H]+ calcd for C16H13N3O2Cl, 314.0696; found, 314.0695.
7-(3-Methyl-1H-1,2,4-triazol-5-yl)-5-(methylamino)-1,6-
naphthyridin-8-ol (8). A mixture of 37 (100 mg, 0.33 mmol),
methylamine (327 μL, 0.653 mmol, 2 N in THF), and DIPEA (0.171
mL, 0.980 mmol) in NMP (2 mL) was stirred at 180 °C for 18 h in a
sealed tube. Further, methylamine (327 μL, 0.653 mmol, 2 N in THF)
was added and stirring was continued for further 18 h. The solvent was
evaporated, DCM (3 mL) was added, and the resulting solid was
collected and purified by mass-directed prep. HPLC to give 8 (21 mg,
0.82 mmol, 25%). 1H NMR (DMSO-d6): δ 14.06 (s, 1H), 10.97 (s,
1H), 8.94−8.91 (m, 1H), 8.54 (d, J = 7.9 Hz, 1H), 7.57−7.51 (m, 1H),
7.29 (bs, 1H), 2.97 (d, J = 3.8 Hz, 3H), 2.33 (s, 3H); m/z 257.2 [M +
H]+.
5-(Dimethylamino)-7-(3-methyl-1H-1,2,4-triazol-5-yl)-1,6-
naphthyridin-8-ol (9). A mixture of 37 (100 mg, 0.33 mmol),
dimethylamine (0.327mL, 0.653mmol, 2M inTHF), andDIPEA (171
μL, 0.98 mmol) in NMP (2 mL) was stirred at 180 °C for 18 h in a
sealed tube. Further dimethylamine (0.327 mL, 0.653 mmol, 2 M in
THF) was added and stirring was continued for a further 18 h. The
solvent was evaporated, and the crude residue was purified by flash
chromatography (0−50% EtOAC/EtOH (3:1)/cyclohexanes) to give
9 (34 mg, 0.13 mmol, 38%). 1H NMR (DMSO-d6): δ 14.20 (s, 1H),
11.47 (bs, 1H), 8.99−8.96 (m, 1H), 8.46 (d, J = 8.2Hz, 1H), 7.61−7.56
(m, 1H), 2.93 (s, 6H), 2.35 (s, 3H); m/z [M + H]+ calcd for
C13H15N6O, 271.1307; found, 271.1309.
5-((4-Chlorobenzyl)amino)-7-(3-methyl-1H-1,2,4-triazol-5-
yl)-1,6-naphthyridin-8-ol (10). 10 was synthesized by an analogous
method to 8 from 37 (50 mg, 0.15 mmol), 4-chlorobenzylamine (42
mg, 0.29 mmol), and DIPEA (57 mg, 0.44 mmol) to give 10 (30 mg,
0.074 mmol, 50%). 1H NMR (DMSO-d6): δ 14.18 (bs, 1H), 11.12 (bs,
1H), 9.04−9.01 (m, 1H), 8.75−8.72 (m, 1H), 7.90−7.85 (m, 1H),
7.67−7.62 (m, 1H), 7.54−7.50 (m, 2H), 7.37−7.33 (m, 2H), 4.89 (s,
2H), 2.43 (s, 3H); 13HNMR (DMSO-d6): δ 158.8, 154.9, 153.5, 149.3,
144.5, 141.2, 140.6, 132.4, 131.4, 130.1, 128.4, 122.7, 121.2, 116.1, 43.4,
14.0; m/z [M + H]+ calcd for C18H16N6OCl, 367.1074; found,
367.1088.
7-(3-Methyl-1H-1,2,4-triazol-5-yl)-5-morpholino-1,6-naph-
thyridin-8-ol (11). A mixture of 37 (50 mg, 0.16 mmol), DIPEA (90
μL, 0.49mmol), andmorpholine (28 μL, 0.32mmol) in NMP (0.5mL)
was heated in microwave to 200 °C for 1 h. After cooling, the crude
mixture was purified by prep. HPLC to give 11 (31 mg, 0.073 mmol,
46%) as the TFA salt. 1HNMR (DMSO-d6): δ 9.13 (dd, J = 1.6, 4.2 Hz,
1H), 8.59 (dd, J = 1.6, 8.5 Hz, 1H), 7.77−7.73 (m, 1H), 3.90−3.85 (m,
4H), 3.34−3.30 (m, 4H), 2.52 (s, 3H, under DMSO signal);m/z 313.2
[M + H]+.
1-(8-Hydroxy-7-(3-methyl-1H-1,2,4-triazol-5-yl)-1,6-naph-
thyridin-5-yl)pyrrolidin-2-one (12). To a solution of pyrrolidin-2-
one (0.068 mL, 0.89 mmol) in 1,4-dioxane (7 mL) was added 38 (300
mg, 0.74 mmol), caesium carbonate (484 mg, 1.48 mmol), palladium
acetate (3 mg, 0.015 mmol), and Xantphos (17 mg, 0.03 mmol), and
the mixture was heated at 65 °C for 18 h. Water (50 mL)/HCl (2 M,
two drops) was added, extracted with DCM (2 × 50 mL), and the
combined organics were dried over Na2SO4, filtered, and solvent-
evaporated. The crude residue (120 mg, 0.30 mmol) in DMF (0.3 mL)
was added to a solution of sodium methoxide (1.5 mL, 0.74 mmol, 0.5
M in MeOH) and heated to 50 °C for 5 min, cooled to room
temperature, and stirred for 15 min. Acetic acid (0.033 mL, 0.59 mmol)
and water (3 mL) were added dropwise, and the resulting suspension
was stirred for 2 h, poured into water (20 mL), and the pH adjusted to
approximately 5 by addition of HCl (1 M, 0.1 mL). DCM (20 mL) was
added, and the organic layer was dried over Na2SO4, filtered, and
concentrated to afford crude 8-hydroxy-5-(2-oxopyrrolidin-1-yl)-1,6-
naphthyridine-7-carbonitrile (57 mg, 0.22 mmol, 25% over two steps).
To this crude intermediate in a mixture of acetic acid (0.1 mL) and 1,4-
dioxane (1 mL) was added acetic hydrazide (50 mg, 0.67 mmol), and
the mixture was heated in microwave to 180 °C for 2 h. Further, acetic
hydrazide (50 mg, 0.67 mmol) was added and heated in microwave to
180 °C for 2 h. The solvent was evaporated, and the crude material was
purified by prep. HPLC to give 12 (5 mg, 0.016 mmol, 7%). 1H NMR
(DMSO-d6): δ 14.48 (bs, 1H), 12.25 (bs, 1H), 9.18−9.15 (m, 1H),
8.39−8.35 (m, 1H), 7.78−7.73 (m, 1H), 4.15−4.08 (m, 2H), 2.66−
2.60 (m, 2H), 2.49 (s, 3H, under solvent peak), 2.32−2.23 (m, 2H);m/
z 311.1 [M + H]+.
2-(8-Hydroxy-7-(3-methyl-1H-1,2,4-triazol-5-yl)-1,6-naph-
thyridin-5-yl)-1,2-thiazinane 1,1-dioxide (13). To a solution of 38
(300 mg, 0.74 mmol) in 1,4-dioxane (7 mL) were added 1,2-thiazinane
1,1-dioxide (120 mg, 0.89 mmol), caesium carbonate (484 mg, 1.48
mmol), Pd2(dba)3 (13 mg, 0.015 mmol), and Xantphos (17 mg, 0.03
mmol), and the resulting mixture was stirred at 65 °C for 1 h. The
mixture was poured into water (50 mL)/HCl (2 M, two drops) and
extracted with DCM (2 × 50 mL). The combined organics were dried
over Na2SO4, filtered, and solvent-evaporated. The crude mixture in
DMF (0.6 mL) was added to a solution of sodium methoxide (2.7 mL,
1.36mmol, 0.5M inMeOH), and the resulting solution heated to 50 °C
for 5 min, cooled to room temperature, and stirred 15 min. An acetic
acid (0.06 mL, 1.09 mmol)/water (5.5 mL) mixture was added
dropwise, and the resulting suspension was stirred for 2 h, poured into
water (20mL), and the pHwas adjusted to approximately 5 by addition
of HCl (1 M, 0.1 mL). DCM (20 mL) was added, and the organic layer
was dried over Na2SO4, filtered, and concentrated to afford crude 5-
(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-car-
bonitrile (190 mg, 0.53 mmol, 71% over two steps). To this crude
material in a mixture of acetic acid (0.1 mL) and 1,4-dioxane (1 mL)
was added acetic hydrazide (139 mg, 1.83 mmol), and the mixture was
stirred in microwave at 180 °C for 2 h, concentrated to dryness, and
purified by mass-directed prep. HPLC to give 13 (35 mg, 0.1 mmol,
16%). 1H NMR (DMSO-d6): δ 14.45 (bs, 1H), 12.41 (bs, 1H), 9.09−
9.06 (m, 1H), 8.51−8.45 (m, 1H), 7.78−7.70 (m, 1H), 4.02−3.97 (m,
1H), 3.89−3.81 (m, 1H), 3.70−3.61 (m, 2H), 3.38−3.31 (m, 2H),
3.09−3.06 (m, 1H), 2.23 (s, 3H), 1.57−1.48 (m, 1H); m/z [M + H]+
calcd for C15H17N6O3S, 361.1083; found, 361.1079.
7-(3-Methyl-1H-1,2,4-triazol-5-yl)-5-phenyl-1,6-naphthyri-
din-8-ol (14). 36 (75 mg, 0.39 mmol), 4,4,5,5-tetramethyl-2-phenyl-
1,3,2-dioxaborolane (122 mg, 0.60 mmol), potassium phosphate
tribasic (191 mg, 0.90 mmol), and Pd(dppf)Cl2·CH2Cl2 (12 mg,
0.015 mmol) in DMF (1.5 mL)/water (0.5 mL) were heated in
microwave at 130 °C for 1 h. EtOAc (10 mL) and 20% aqueous NaCl
(10 mL) were added, and the organic layer was separated, washed with
brine, and solvent-evaporated to give crude intermediate. To this crude
material in 1,4-dioxane (2 mL)/acetic acid (0.2 mL) was added
acetylhydrazide (667 mg, 0.90 mmol) and heated in microwave to 200
°C for 45 min. The resulting mixture was filtered to remove solid,
solvent-evaporated, and purified by mass-directed prep. HPLC to give
14 (3 mg, 0.009 mmol, 3%). 1H NMR (DMSO-d6): δ 13.50 (bs, 1H),
9.15 (s, 1H), 8.37 (d, J = 8.3 Hz, 1H), 7.76−7.66 (m, 3H), 7.63−7.52
(m, 4H), 2.48 (s, 3H, under DMSO signal); m/z 304.1 [M + H]+.
7-(3-Methyl-1H-1,2,4-triazol-5-yl)-5-(2-(trifluoromethyl)-
phenyl)-1,6-naphthyridin-8-ol (15). A mixture of 39 (250 mg, 0.74
mmol), 2-(trifluoromethyl)benzeneboronic acid (279 mg, 1.47 mmol),
sodium carbonate (234 mg, 2.21 mmol), and tetrakis-
(triphenylphosphine)palladium(0) (42 mg, 0.037 mmol) in water (3
mL)/1,4-dioxane (9 mL), was heated in microwave at 120 °C for 1 h.
The mixture was partitioned between DCM (15 mL) and sat. NH4Cl
(30 mL), the phases were separated, and the aqueous layer was further
extracted with DCM (3 × 10 mL). The combined organics were dried
over Na2SO4, filtered, and concentrated, and the resulting solid was
triturated with ether to give a mixture of 8-(benzyloxy)-5-(2-
(trifluoromethyl)phenyl)-1,6-naphthyridine-7-carbonitrile and 8-hy-
droxy-5-(2-(trifluoromethyl)phenyl)-1,6-naphthyridine-7-carbonitrile
(0.150 g). The crude mixture was taken up in acetic acid (0.1 mL)/1,4-
dioxane (1 mL), acetic hydrazide (46 mg, 0.62 mmol) was added, and
heated in microwave at 180 °C for 8 h. Further, acetic hydrazide (0.031
g, 0.416 mmol) was added and heating was continued for 17 h. The
solvent was evaporated, and the crude mixture was dissolved in 5%
MeOH/DCM (20 mL), washed with water (1 × 50 mL), and the
aqueous phase was extracted with further DCM (1 × 30 mL). The
combined organics were washed with water, dried over Na2SO4,
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filtered, and concentrated to give a brown oil, which was precipitated
with a mixture of ether and acetone. The resulting solid was further
triturated with ether to give a brown pale solid, which was dried under
vacuum to give 15 (60 mg, 0.16 mmol, 22% over two steps). 1H NMR
(CDCl3): δ 9.23−9.20 (m, 1H), 7.96−7.89 (m, 2H), 7.77−7.69 (m,
2H), 7.57−7.47 (m, 2H), 2.59 (s, 3H); m/z 372.1 [M + H]+.
5-(2-Methoxyphenyl)-7-(3-methyl-1H-1,2,4-triazol-5-yl)-1,6-
naphthyridin-8-ol (16). A mixture of 39 (700 mg, 2.06 mmol), 2-
methoxyphenylboronic acid (626 mg, 4.12 mmol), sodium carbonate
(655 mg, 6.18 mmol), and tetrakis(triphenylphosphine)palladium(0)
(120mg, 0.103mmol) in 1,4-dioxane (9mL)/water (3mL) was heated
at 120 °C in microwave for 1.5 h, poured into water (15 mL)/brine (5
mL), and extracted with EtOAc (20 mL). The organics were dried over
MgSO4, filtered, and concentrated. The crude was dissolved in acetic
acid (0.5 mL)/1,4-dioxane (5 mL), acetic hydrazide (0.23 g, 3.10
mmol) was added, and stirred at 180 °C in microwave for 2 h. Further,
acetic hydrazide (0.23 g, 3.10 mmol) was added and the mixture was
heated in microwave at 180 °C for 6 h. The resulting solution was
concentrated and taken up in 9:1 DCM/MeOH (15 mL), washed with
water (10 mL), brine (5 mL), dried over Na2SO4, filtered, and
concentrated. The resulting solid was triturated with ether (10mL) and
acetonitrile (10 mL) to give 16 (165 mg, 0.50 mmol, 24%). 1H NMR
(MeOD): δ 9.09−9.05 (m, 1H), 8.09−8.05 (m, 1H), 7.68−7.63 (m,
1H), 7.58−7.53 (m, 1H), 7.50−7.46 (m, 1H), 7.22−7.13 (m, 2H), 3.71
(s, 3H), 3.32 (s, 3H); m/z [M + H]+ calcd for C18H16N5O2, 334.1304;
found, 334.1294.
5-(2-Methoxyphenyl)-7-(5-methyl-1,3,4-oxadiazol-2-yl)-1,6-
naphthyridin-8-ol (19). 41 (80 mg, 0.25 mmol), 2-methoxyphe-
nylboronic acid (76 mg, 0.50 mmol), sodium carbonate (79 mg, 0.747
mmol), and tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.012
mmol) in a mixture of water (1 mL)/1,4-dioxane (3 mL) were stirred at
120 °C overnight. The reaction mixture was concentrated to dryness,
and the crude residue was purified by flash chromatography (0−70%
EtOH/EtOAc (1:3)/cyclohexane) to give 2-(8-methoxy-5-(2-methox-
yphenyl)-1,6-naphthyridin-7-yl)-5-methyl-1,3,4-oxadiazole (86 mg,
0.25 mmol). 1H NMR (DMSO-d6): δ 9.16−9.14 (m, 1H), 7.95−7.92
(m, 1H), 7.69−7.65 (m, 1H), 7.51−7.46 (m, 1H), 7.32−7.29 (m, 1H),
7.18−7.15 (m, 1H), 7.08−7.04 (m, 1H), 4.19 (s, 3H), 3.58 (s, 3H),
2.53 (s, 3H). To a solution of 2-(8-methoxy-5-(2-methoxyphenyl)-1,6-
naphthyridin-7-yl)-5-methyl-1,3,4-oxadiazole (68 mg, 0.195 mmol) in
CH3CN (2 mL) were added trimethylchlorosilane (37 μL, 0.293
mmol) and sodium iodide (44 mg, 0.293 mmol) and heated to reflux
overnight. The crude residue was poured into water (30 mL) and
extracted with DCM (50 mL). The organic layer was dried over
Na2SO4, filtered, and concentrated. The crude residue was triturated
withMeOH(5mL), and the resulting solid was collected by filtration to
give 19 (29mg, 0.087 mmol, 44%). 1HNMR (DMSO-d6): δ 9.19 (dd, J
= 1.5, 4.0 Hz, 1H), 7.99 (dd, J = 1.5, 8.6 Hz, 1H), 7.77 (dd, J = 4.2, 8.5
Hz, 1H), 7.58−7.53 (m, 1H), 7.40−7.37 (m, 1H), 7.23 (d, J = 8.1 Hz,
1H), 7.15 (dd, J = 7.3, 7.3 Hz, 1H), 3.66 (s, 3H), 2.62 (s, 3H). 13CNMR
(DMSO-d6): δ 164.1, 163.6, 157.2, 153.9, 150.1, 149.6, 141.9, 136.7,
131.7, 131.1, 126.9, 125.1, 124.5, 122.9, 121.2, 111.9, 55.8, 11.1; m/z
[M + H]+ calcd for C18H15N4O3, 335.1144; found, 335.1155.
(R)-N-(1-(4-Fluorophenyl)ethyl)-1-methyl-4-oxo-1,4-dihy-
dro-1,5-naphthyridine-3-carboxamide (22). To 42 (100 mg, 0.47
mmol) in DMF (2mL) were added 4-fluoro-α-(R)-methylbenzylamine
(71 mg, 0.51 mmol) and DIPEA (180 mg, 1.40 mmol).
Propylphosphonic anhydride (444 mg, 1.4 mmol, 50% solution in
EtOAc) was added dropwise, and the mixture was stirred for 2 h,
poured into sat NaHCO3 (10 mL), and extracted into EtOAc (3 × 10
mL). The combined organics were washed with brine, dried,
evaporated, and the crude material was purified by column
chromatography (0−20% MeOH/DCM) to give 22 (13 mg, 0.38
mmol, 8%). 1H NMR (DMSO-d6): δ 10.49 (d, J = 7.8 Hz, 1H), 8.88−
8.85 (m, 2H), 8.35−8.31 (m, 1H), 7.89−8.85 (m, 1H), 7.46−7.40 (m,
2H), 7.21−7.15 (m, 2H), 5.24−5.15 (m, 1H), 4.02 (s, 3H), 1.51 (d, J =
6.9 Hz, 3H); m/z 326.1 [M + H]+.
N-(4-Methoxybenzyl)-1-methyl-4-oxo-1,4-dihydropyrido-
[3,2-c]pyridazine-3-carboxamide (23). To crude 43 (8 g, 33.4
mmol) in MeCN (130 mL) at 0 °C were added triethylamine (6 g, 60
mmol) and 4-acetamidobenzenesulfonyl azide (8.8 g, 36.8 mmol),
allowed to warm to RT, and stirred for 18 h. The crude mixture was
filtered to remove solid, and the filtrate was concentrated and purified
by column chromatography (pet. ether/EtOAc, 3:1) to give tert-butyl
2-diazo-3-(3-fluoropyridin-2-yl)-3-oxopropanoate (8.1 g, 30.5 mmol,
91%). This material was dissolved in THF (80 mL), tributylphosphine
(6.854 g, 33.6 mmol) was added, stirred for 15 min, and quenched by
addition of water (5.5mL). The solvent was evaporated, and the residue
was purified by flash chromatography (pet. ether/EtOAc 3:1) to give
tert-butyl-3-(3-fluoropyridin-2-yl)-2-hydrazono-3-oxopropanoate (9 g,
quant.). This material was dissolved in MeCN (180 mL), and DBU
(10.7 g, 10.7 mmol) and methyl iodide (5 g, 35.3 mmol) were added
and stirred at RT for 18 h. The mixture was quenched with sat. aq
NH4Cl, extracted into DCM, and the organics were concentrated and
purified by flash chromatography (1% MeOH in DCM) to give crude
44, which was used without further purification (2.8 g, 10.7 mmol,
32%); m/z 206.0 [M + H − tBu]+. To a solution of 44 (2.8 g, 10.7
mmol) in DCM (100 mL) was added TFA (15.7 g, 139 mmol) and
stirred for 18 h. Ether was added and evaporated and further ether
added. The resulting solid was collected and dried to give crude 1-
methyl-4-oxo-1,4-dihydropyrido[3,2-c]pyridazine-3-carboxylic acid
(1.6 g, 73%), which was used without purification.
A mixture of the crude material (300 mg, 1.46 mmol), HOBt (237
mg, 1.75 mmol), EDCI (420 mg, 2.19 mmol), and DIPEA (378 mg,
2.92 mmol) in DCM (12 mL) was stirred for 30 min, a solution of (4-
methoxyphenyl)methanamine (241 mg, 1.75 mmol) in DCM (12 mL)
added, and stirred for 16 h. The mixture was concentrated and purified
by prep. HPLC to give 23 (419 mg, 1.29 mmol, 88%). 1H NMR
(DMSO-d6): δ 9.87−9.84 (m, 1H), 8.93 (d, J = 4.2Hz, 1H), 8.43 (d, J =
8.8 Hz, 1H), 7.96−7.94 (m, 1H), 7.31 (d, J = 8.1 Hz, 2H), 6.91 (d, J =
8.2 Hz, 2H), 4.50 (d, J = 5.8 Hz, 2H), 4.24 (s, 3H), 3.75 (s, 3H); 13C
NMR (DMSO-d6): δ 169.3, 162.0, 158.8, 150.1, 141.3, 140.3, 139.0,
131.4, 129.2, 128.9, 127.0, 114.3, 55.5, 44.9, 42.3; m/z [M + H]+ calcd
for C17H17N4O3, 325.1295; found, 325.1305.
(R)-N-(Fluoro(4-methoxyphenyl)methyl)-5-hydroxy-2-(2-
methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-
carboxamide (25). To a suspension of 46 (240 mg, 0.79 mmol) in
toluene (5 mL), (R)-4-fluoro-α-methylbenzylamine (549 mg, 3.94
mmol) was added. The resulting solution was heated to reflux
overnight. The solvent was evaporated, and the residue was purified by
prep. HPLC to give 25 (145 mg, 46% yield). 1H NMR (DMSO-d6): δ
12.55−12.48 (m, 1H), 9.07−9.02 (m, 1H), 7.56−7.50 (m, 1H), 7.47−
7.40 (m, 3H), 7.20−7.09 (m, 4H), 5.17 (dd, J = 8.0, 15.3 Hz, 1H), 3.81
(d, J = 7.3 Hz, 3H), 3.17 (d, J = 3.0 Hz, 3H), 1.50 (dd, J = 2.7, 6.9 Hz,
3H); m/z 398.2 [M + H]+.
8-Hydroxy-5-(2-methoxyphenyl)-N-methyl-1,6-naphthyri-
dine-7-carboxamide (26). To a mixture of 51a (72 mg, 0.25 mmol),
(2-methoxyphenyl)boronic acid (77 mg, 0.51 mmol), and potassium
phosphate tribasic (162 mg, 0.77 mmol) in 1,4-dioxane (2 mL) was
added Pd(dppf)Cl2.DCM (12 mg, 0.015 mmol) in water (0.5 mL) and
heated in microwave at 140 °C for 1 h. After cooling, EtOAc (9 mL)
and 20% aqueous NaCl (10 mL) were added and the organics were
separated, dried over MgSO4, evaporated, and the crude material was
purified by column chromatography (0−8% MeOH/DCM) to give 26
(25 mg, 0.077 mmol, 30%). 1H NMR (DMSO-d6): δ 9.17−9.15 (m,
1H), 9.02−8.98 (m, 1H), 7.95−7.92 (m, 1H), 7.75−7.72 (m, 1H),
7.58−7.54 (m, 1H), 7.44−7.42 (m, 1H), 7.25−7.22 (m, 1H), 7.18−
7.15 (m, 1H), 3.68 (s, 3H), 2.91 (d, J = 4.9 Hz, 3H). 13C NMR
(DMSO-d6): δ 170.3, 157.2, 154.1, 148.6, 142.5, 136.4, 132.0, 131.0,
127.1, 125.9, 125.1, 121.2, 111.8, 55.8, 26.3; m/z [M + H]+ calcd for
C17H16N3O3, 310.1192; found, 310.1196.
8-Hydroxy-N-(4-methoxybenzyl)-1,6-naphthyridine-7-car-
boxamide (27). A mixture of 47 (100 mg, 0.50 mmol) and 4-
methoxybenzylamine (134 mg, 0.98 mmol) in EtOH (20 mL) was
heated to reflux overnight. To the hotmixture was addedwater (30mL)
and acetic acid (2mL), cooled to RT, solvent-evaporated, and the crude
material was purified by mass-directed prep. HPLC to give 27 (84 mg,
0.27 mmol, 54%). 1H NMR (DMSO-d6): δ 13.69 (bs, 1H), 9.83 (bs,
1H), 9.19−9.14 (m, 1H), 8.93−8.85 (m, 1H), 8.60 (d, J = 8.3 Hz, 1H),
7.83−7.79 (m, 1H), 7.35−7.32 (m, 2H), 6.92−6.89 (m, 2H), 4.49 (d, J
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= 6.4 Hz, 2H), 3.75 (s, 3H). 13C NMR (DMSO-d6): δ 169.8, 158.8,
154.9, 154.4, 142.5, 136.5, 131.3, 129.5, 127.0, 126.1, 125.4, 114.2, 55.5,
42.1;m/z [M +H]+ calcd for C17H16N3O3, 310.1192; found, 310.1192.
N-(1-(4-Fluorophenyl)ethyl)-8-hydroxy-1,6-naphthyridine-
7-carboxamide (28). A mixture of 47 (300 mg, 1.4 mmol) and 4-
fluoro-α-methylbenzylamine (383 mg, 2.7 mmol) in EtOH (12 mL)
was heated in microwave at 120 °C for 2 h. After cooling to 50 °C, water
(10mL) and acetic acid (1 mL) were added and themixture was cooled
to RT. Further, water (10 mL) and acetic acid (1 mL) were added, the
mixture was stirred for 40 min, and the resulting solid was collected,
washed with water, and dried to give 28 (280 mg, 0.89 mmol, 65%). 1H
NMR (DMSO-d6): δ 13.69 (s, 1H), 9.66−9.60 (m, 1H), 9.18−9.15 (m,
1H), 8.93 (s, 1H), 8.64−8.61 (m, 1H), 7.85−7.81 (m, 1H), 7.57−7.51
(m, 2H), 7.20−7.15 (m, 2H), 5.31−5.24 (m, 1H), 1.59 (d, J = 7.0 Hz,
3H). 13C NMR (DMSO-d6): δ 169.2, 161.6 (d, J = 242 Hz), 154.9,
154.6, 142.4, 140.5, 136.5, 128.9, (d, J = 8.1 Hz), 127.0. 125.9, 125.4,
115.5 (d, J = 21.3 Hz), 48.2, 22.1; m/z [M + H]+ calcd for
C17H15N3O2F, 312.1148; found, 312.1139.
N-(Cyclopropylmethyl)-8-hydroxy-1,6-naphthyridine-7-car-
boxamide (29). 29 was synthesized by an analogous method to 28
from 47 (100 mg, 0.50 mmol) and aminomethylcyclopropane (70 mg,
0.98 mmol) to give 29 (23 mg, 0.09 mmol, 19%). 1H NMR (DMSO-
d6): δ 13.92 (bs, 1H), 9.38 (bs, 1H), 9.18−9.16 (m, 1H), 8.92 (s, 1H),
8.64−8.60 (m, 1H), 7.86−7.81 (m, 1H), 3.26 (t, J = 6.6 Hz, 2H), 1.19−
1.11 (m, 1H), 0.49−0.45 (m, 2H), 0.34−0.29 (m, 2H). 13C NMR
(DMSO-d6): δ 169.8, 154.8, 154.5, 142.5, 142.3, 136.4, 126.9, 126.2,
125.2, 43.6, 11.3, 3.8; m/z 244.1 [M + H]+.
N-(4-Fluorobenzyl)-5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hy-
droxy-1,6-naphthyridine-7-carboxamide (30). To a solution of
49 (365 mg, 0.835 mmol) in 1,4-dioxane (8.4 mL), 1,2-thiazinane 1,1-
dioxide (135mg, 1.00mmol), caesium carbonate (544mg, 1.67mmol),
Pd2(dba)3 (15 mg, 0.017 mmol), and Xantphos (19 mg, 0.033 mmol)
were added, and the resulting mixture was stirred at 65 °C for 2.5 h. The
reaction was partitioned between DCM (25 mL) and sat. NH4Cl (50
mL), the phases were separated, and the aqueous phase was extracted
with further DCM (1 × 25 mL). The combined organic layers were
dried over Na2SO4, filtered, and concentrated to give a crude material,
which was dissolved in dichloromethane and purified by flash
chromatography (0−30% ethyl acetate/ethanol (3:1)/cyclohexane)
to give methyl 5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-(tosyloxy)-1,6-
naphthyridine-7-carboxylate, which was used without further purifica-
tion. To a suspension of the crude material (0.070 g, 0.142 mmol) in
isopropanol (1.4 mL), a solution of lithium hydroxide (20 mg, 0.47
mmol) in water was added, and the resulting suspension was heated at
60 °C overnight and then stirred at room temperature overnight. 2 M
HCl was added to adjust the pH to approximately 2, and the mixture
was concentrated to give crude 5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-
hydroxy-1,6-naphthyridine-7-carboxylic acid. To a suspension of the
crude material (108 mg, 0.33 mmol) in DMF (3.3 mL), 4-
fluorobenzylamine (0.045 mL, 0.40 mmol), HOBt (61 mg, 0.40
mmol), and DIPEA (0.088 mL, 0.50 mmol) were added, and the
resulting solution was purged with nitrogen and cooled to 0 °C. EDCI
(96 mg, 0.50 mmol) was added, and the solution was stirred at room
temperature for 8 h and then at 50 °C overnight. Further, HOBt (61
mg, 0.40 mmol), EDCI (96 mg, 0.50 mmol), and 4-fluorobenzylamine
(0.046 mL, 0.40 mmol) were added, and the resulting solution was
stirred at 50 °C overnight. After cooling, the reaction was partitioned
between EtOAc (20 mL) and sat. NH4Cl (50 mL), the layers were
separated, and the aqueous phase was extracted with further EtOAc (1
× 20 mL). The combined organics were dried over Na2SO4, filtered,
and concentrated to give a crude oil, which was purified by preparative
HPLC to give 30 (11 mg, 0.025 mmol, 7% over three steps). 1H NMR
(DMSO-d6): δ 9.15 (bs, 1H), 8.61−8.59 (m, 1H), 7.84−7.80 (m, 1H),
7.49−7.43 (m, 2H), 7.37−7.25 (m, 1H), 7.18−7.12 (m, 2H), 7.11−
7.03 (m, 1H), 4.66 (d, J = 6.0 Hz, 2H), 3.89−3.86 (m, 2H), 3.49−3.45
(m, 2H), 2.36−2.28 (m, 3H), 2.02−1.99 (m, 1H); m/z 431.0 [M +
H]+; m/z [M + H]+ calcd for C20H20N4O4SF, 431.1189; found,
431.1192.
N-(4-Chlorobenzyl)-8-hydroxy-5-((tetrahydro-2H-pyran-4-
yl)amino)-1,6-naphthyridine-7-carboxamide (31). To a solution
of DIPEA (747 μL, 0.428 mmol) in NMP (1.43 mL) were added 4-
aminotetrahydropyran (103 μL, 0.998 mmol) and 51c (56 mg, 0.143
mmol), and the resulting solution was heated in microwave at 180 °C
for 5 h. The reaction was partitioned between EtOAc (15 mL) and a
saturated solution of NaHCO3 (60mL). The layers were separated, and
the aqueous phase was extracted with EtOAc (3 × 30 mL). The organic
phases were combined, dried over Na2SO4, filtered, concentrated, and
the crude material was purified by preparative HPLC to afford 31 (10
mg, 17%). 1H NMR (DMSO-d6): δ 12.43 (s, 1H), 9.07−9.02 (m, 2H),
8.78 (dd, J = 1.5, 8.6 Hz, 1H), 7.69 (dd, J = 4.3, 8.3 Hz, 1H), 7.43−7.35
(m, 4H), 7.00 (d, J = 7.6 Hz, 1H), 4.58 (d, J = 6.3 Hz, 2H), 4.47−4.39
(m, 1H), 3.92−3.88 (m, 2H), 3.55−3.47 (m, 2H), 1.97−1.90 (m, 2H),
1.62−1.50 (m, 2H); m/z 413.17 [M + H]+.
N-(4-Chlorobenzyl)-8-hydroxy-5-morpholino-1,6-naphthyr-
idine-7-carboxamide (32). A mixture of 51c (30 mg, 0.07 mmol)
and morpholine (312 mg, 0. 36 mmol) in NMP (0.5 mL) was heated in
microwave at 150 °C for 1 h. The crude solution was purified by mass-
directed prep. HPLC to give 32 (10 mg, 0.024 mmol, 33%). 1H NMR
(DMSO-d6): δ 13.14 (bs, 1H), 9.45−9.32 (m, 1H), 9.16−9.07 (m,
1H), 8.62−8.53 (m, 1H), 7.81−7.70 (m, 1H), 7.45−7.38 (m, 4H),
4.62−5.53 (m, 2H), 3.92−3.81 (m, 4H), 3.30−3.23 (m, 4H, under
water signal); m/z 399.1, 401.1 [M + H]+.
N-(Cyclopropylmethyl)-8-hydroxy-5-(2-methoxyphenyl)-
1,6-naphthyridine-7-carboxamide (33). 33 was synthesized by an
analogous method to 26 from 51b (40 mg, 0.14 mmol) and 2-
methoxyphenylboronic acid (43 mg, 0.28 mmol) to give 33 (20 mg,
0.05 mmol, 38%). 1H NMR (DMSO-d6): δ 13.51 (s, 1H), 9.17−9.15
(m, 1H), 8.28−8.23 (m, 1H), 8.00−7.96 (m, 1H), 7.58−7.44 (m, 3H),
7.21−7.17 (m, 1H), 7.12−7.09 (m, 1H), 3.74 (s, 3H), 3.40−3.35 (m,
2H), 1.16−1.08 (m, 1H), 0.61−0.56 (m, 2H), 0.36−0.311 (m, 2H);m/
z 350.2 [M + H]+.
8-Hydroxy-N-(trans-4-methoxycyclohexyl)-5-(2-methoxy-
phenyl)-1,6-naphthyridine-7-carboxamide (34). To a solution of
50 (750 mg, 2.53 mmol) in DMF (17 mL) were added trans-4-
methoxycyclohexanamine (491 mg, 3.80 mmol), DIPEA (1.33 mL,
7.59 mmol), and propylphosphonic anhydride solution (T3P) (4.83 g,
7.59 mmol) and stirred at RT for 2 h and then at 50 °C for 18 h. After
cooling, the reaction mixture was partitioned between water (70 mL)
and EtOAc (30 mL), the layers were separated, and the pH of the
aqueous layer was adjusted to approximately 5 with 1 M NaOH. The
aqueous layer was extracted with EtOAc (2 × 30 mL), and the
combined organics were washed with sat. NH4Cl (1 × 40 mL), dried
over Na2SO4, filtered, and concentrated. The resulting solid was
triturated with ether (3 × 5 mL) and dried to give 34 (580 mg, 1.42
mmol, 56% yield). 1H NMR (DMSO-d6): δ 13.88 (s, 1H), 9.14−9.12
(m, 1H), 8.67−8.64 (m, 1H), 7.90−7.88 (m, 1H), 7.72−7.70 (m, 1H),
7.57−7.52 (m, 1H), 7.32−7.40 (m, 1H), 7.22−7.13 (m, 2H), 3.92−
3.84 (m, 1H), 3.64 (s, 3H), 3.23 (s, 3H), 3.11−3.05 (m, 1H), 2.05−
1.99 (m, 2H), 1.85−1.83 (m, 2H), 1.63−1.54 (m, 2H), 1.27−1.17 (m,
2H); 13C NMR (DMSO-d6): δ 169.2, 157.2, 154.3, 154.1, 148.6, 142.4,
136.4, 131.9, 131.1, 127.0, 125.9, 121.2, 111.8, 78.1, 55.8, 55.6, 48.1,
30.8, 29.8; m/z [M + H]+ calcd for C23H26N3O4, 408.1923; found,
408.1913.
5-Bromo-8-hydroxy-1,6-naphthyridine-7-carbonitrile (36).
To a solution of 35 (1.10 g, 6.43 mmol) in DCM (64 mL), NBS
(1.37 g, 7.71 mmol) was added and stirred for 2 h. Water (100 mL) was
added, the phases were separated, and the aqueous layer was extracted
with 5% MeOH/DCM (3 × 40 mL). The combined organics were
washed with water (4 × 100 mL), dried over Na2SO4, filtered, and
concentrated to give 36 as a yellow solid (1.35 g, 5.42 mmol, 84%). 1H
NMR (DMSO-d6): 9.30−9.28 (m, 1H), 8.64−8.61 (m, 1H), 8.06−
8.02 (m, 1H); δ m/z 250.0, 252.0 [M + H]+.
5-Bromo-7-(5-methyl-4H-1,2,4-triazol-3-yl)-1,6-naphthyri-
din-8-ol (37). To 36 (750 mg, 2.85 mmol) in 1,4-dioxane (6 mL)/
acetic acid (2 mL) was added acetohydrazide (666 mg, 9.0 mmol) and
heated in microwave at 200 °C for 0.5 h. Upon cooling, the resulting
solid was collected, washed with 1,4-dioxane, and dissolved in water. 1
M HCl was added to adjust the pH to approximately 4−5, and the
resulting solid was collected, washed with water, and dried in vacuo to
give 37 (460 mg, 1.35 mmol, 45%). 1H NMR (DMSO-d6): δ 14.14 (bs,
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1H), 8.83−8.82 (m, 1H), 8.27−8.24 (m, 1H), 7.63−7.60 (m, 1H), 2.31
(s, 3H); m/z 305.9, 307.9 [M + H]+.
5-Bromo-7-cyano-1,6-naphthyridin-8-yl 4-methylbenzene-
sulfonate (38). To a suspension of 36 (500 mg, 2.0 mmol) in DCM
(15 mL) were added triethylamine (418 μL, 3.00 mmol) and tosyl
chloride (457 mg, 2.4 mmol) and heated in a sealed tube at 40 °C for 3
h. After cooling, sat. NaHCO3 (25 mL) was added, the layers were
separated, and the aqueous layer was extracted with DCM (30 mL).
The combined organics were dried over Na2SO4, filtered, concentrated,
and purified by flash chromatography (0−80% EtOAc/cyclohexane) to
give 38 (867 g, 1.66 mmol, 83%); 1H NMR (DMSO-d6): δ 9.01−9.00
(m, 1H), 8.62−8.60 (m, 1H), 7.92−7.89 (m, 1H), 7.77 (d, J = 8.4 Hz,
2H), 7.38 (d, J = 8.3 Hz, 2H), 2.36 (s, 3H);m/z 406.0. 408.0 [M +H]+.
8-(Benzyloxy)-5-bromo-1,6-naphthyridine-7-carbonitrile
(39). To a solution of 38 (2.47 g, 9.9 mmol) in THF (60 mL) at 0 °C
was added triphenylphosphine (3.89 g, 14.8 mmol) and benzyl alcohol
(1.12 mL, 10.9 mmol), stirred for 15 min, and diisopropyl
azodicarboxylate (2.91 mL, 14.82 mmol) was added dropwise. The
resulting solution was stirred at 0 °C for 2 h, allowed to warm to room
temperature, and stirred overnight. The solution was poured into water
(150 mL) and extracted with EtOAc (150 mL). The organic layer was
dried over Na2SO4, filtered, concentrated, and purified using column
chromatography (0−25% EtOAc/cyclohexane) to give a white solid,
which was triturated with a mixture of Et2O and cyclohexane (1:1, 20
mL) to give 39 (0.5 g, 1.47 mmol, 15%). 1H NMR (DMSO-d6): δ
9.40−9.37 (m, 1H), 8.72−8.68 (m, 1H), 8.08−8.04 (m, 1H), 7.53−
7.48 (m, 2H), 7.43−7.35 (m, 3H), 5.86 (s, 2H);m/z 338.1, 340.1 [M +
H]+.
2-(5-Bromo-8-methoxy-1,6-naphthyridin-7-yl)-5-methyl-
1,3,4-oxadiazole (41). To a solution of EDCI (335 mg, 1.75 mmol)
in DCM (15 mL) at 0 °C were added DIPEA (0.509 mL, 2.91 mmol)
and HOBt (268 mg, 1.75 mmol) and stirred at 0 °C for 10 min.
Acethydrazide (130mg, 1.75 mmol) and 40 (330mg, 1.17 mmol) were
added, and the solution was stirred for 18 h. Water (25 mL) and DCM
(25mL) were added, and the aqueous layer was extracted with DCM (2
× 15 mL). The combined organics were dried over Na2SO4, filtered,
and concentrated to give crude N′-acetyl-5-bromo-8-methoxy-1,6-
naphthyridine-7-carbohydrazide (170 mg, 43%) which was used
without purification. Triphenylphosphine (247 mg, 0.944 mmol),
carbon tetrachloride (0.182 mL, 1.89 mmol), and triethylamine (0.132
mL, 0.944 mmol) were added to a mixture of the crude material (160
mg, 0.472 mmol) in CH3CN (4 mL) and stirred at 60 °C for 2 h. After
cooling, the reaction mixture was concentrated and purified by flash
chromatography (0−70% EtOH/EtOAc 1:3/cyclohexane) to give 41
(0.08 g, 53% yield). 1H NMR (DMSO-d6): δ 9.34−9.33 (m, 1H),
8.76−8.73 (m, 1H), 8.00−7.97 (m, 1H), 4.25 (s, 3H), 2.66 (s, 3H);m/
z 321.0, 323.0 [M + H]+.
1-Methyl-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carbox-
ylic Acid (42). To 3-chloropyridine-2-carboxylic acid (1 g, 6.3 mmol)
in DCM (40 mL) was added oxalyl chloride (1.6 g, 12.7 mmol) and
DMF (one drop) and stirred for 2 h. The solvent was evaporated, and
THF (20 mL) was added. In parallel, to 3-ethoxy-3-oxo-propanoic acid
(1.31 g, 10.2 mmol) in THF (20 mL) at −78 °C was added BuLi (4.3
mL, 2.5 M in hexanes, 10.8 mmol) dropwise over 10 min. To this was
added the acid chloride solution dropwise, and the mixture was stirred
at −78 °C for 30 min, warmed to −30 °C, and stirred again for 30 min,
and then quenched by pouring into a mix of ice/1MHCl. The aqueous
layer was extracted with EtOAc (3 × 20 mL), and the combined
organics were washed with sat NaHCO3, 1MHCl, and brine, dried, and
evaporated. The crude material (480 mg, 1.9 mmol) and DMF·DMA
(2.49 g, 2.1 mmol) in DMF (2mL)were heated inmicrowave at 100 °C
for 1 h and solvent-evaporated. Water (5 mL) was added and washed
with EtOAc (2 × 5 mL). The combined organics were washed with
brine, dried, and solvent-evaporated. Ether (4 mL)/EtOH (1 mL) and
methylamine (33% in EtOH, 60 mg, 1.9 mmol) were added and stirred
for 1 h, and the resulting solid was collected, taken up in DMF (4 mL),
potassium carbonate (424 mg, 3.0 mmol) was added, and the mixture
was stirred in a sealed tube at 100 °C overnight. The solvent was
evaporated, 1 M NaOH (1 mL)/MeOH (1 mL) was added, and the
mixture was stirred for 2 h. The resulting solid was collected, suspended
in water (5 mL), and acidified with acetic acid. The resulting solid was
collected, washed with water, and dried under vacuum to give 42 (151
mg, 0.70 mmol, 69% yield). 1H NMR (DMSO-d6): δ 15.32 (bs, 1H),
9.11 (bs, 1H), 8.98−8.96 (m, 1H), 8.48−8.44 (m, 1H), 8.00−7.97 (m,
1H), 4.11 (s, 3H); m/z 205.1 [M + H]+.
tert-Butyl 3-(3-Fluoropyridin-2-yl)-3-oxopropanoate (43).To
LDA (33 mL, 65.8 mmol, 2 M in THF) at −78 °C was added tert-butyl
acetate (9.5 g, 82.2 mmol), stirred for 45 min, and methyl 3-
fluoropicolinate (5.1 g, 32.9 mmol) in THF (30 mL) was added
dropwise. The reaction mixture was stirred for 2 h, quenched at−78 °C
by addition of pet. ether and water, and warmed to RT. The layers were
separated, and the aqueous phase was extracted with pet. ether. The
combined organics were dried over Na2SO4, filtered, and evaporated to
give crude 43, which was used in the synthesis of 23without purification
(8 g, quant.); m/z 205.1 [M + H]+.
Ethyl 5-(2-Ethoxy-2-oxoethyl)-3-(2-methoxyphenyl)-2-
methyl-2,5-dihydro-1,2,4-oxadiazole-5-carboxylate (45). To a
mixture of 2-methoxybenzonitrile (500 mg, 3.76 mmol) and N-
methylhydroxylamine hydrochloride (627 mg, 7.51 mmol) in water
(3.8 mL)/EtOH (1.9 mL) was added sodium carbonate (438 mg, 4.13
mmol), and the mixture was stirred at 80 °C for 28 h. The solvent was
evaporated, DCM was added, stirred for 18 h, and the mixture was
filtered. The solid was discarded, and the filtrate was evaporated to give
crude N-hydroxy-2-methoxy-N-methylbenzimidamide (742 mg, 4.12
mmol), which was used in the next step without purification. To this
crude material in EtOH (10 mL) was added diethyl acetylenedicarbox-
ylate (771 mg, 4.53 mmol), stirred for 1 h, and the solvent was
evaporated. The crude material was purified by flash chromatography
(0−80% EtOAc/cyclohexane) to give 45 (880 mg, 2.5 mmol, 61%). 1H
NMR (DMSO-d6): δ 7.57−7.53 (m, 1H), 7.49−7.46 (m, 1H), 7.18−
7.16 (m, 1H), 7.07−7.03 (m, 1H), 4.20−4.16 (m, 2H), 4.08 (q, J = 7.0
Hz, 2H), 3.83 (s, 3H), 3.27−3.23 (m, 1H), 2.97−2.93 (m, 1H), 2.91 (s,
3H), 1.24−1.16 (m, 6H); m/z 351.2 [M + H]+.
Ethyl 5-Hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-
dihydropyrimidine-4-carboxylate (46). A solution of 45 (880 mg,
2.51 mmol) in p-xylene (5.38 mL) was heated to reflux for 2 days.
Hexane (5 mL) was added, the resulting mixture was sonicated, and the
resulting suspension was stored at 0 °C for 3 days. The solid was
collected, washed with cyclohexane, and dried to give 46 (540 mg, 1.78
mmol, 41%). 1H NMR (DMSO-d6): δ 10.45 (s, 1H), 7.56−7.51 (m,
1H), 7.37−7.34 (m, 1H), 7.19−7.17 (m, 1H), 7.11−7.07 (m, 1H), 4.28
(q, J = 6.9 Hz, 2H), 3.82 (s, 3H), 3.20 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H);
m/z 305.1 [M + H]+.
Methyl 5-Bromo-8-hydroxy-1,6-naphthyridine-7-carboxy-
late (48). To 47 (800 mg, 3.9 mmol) in DCM (20 mL) was added
NBS (837 mg, 4.7 mmol) and stirred for 2 h. The resulting solid was
collected, washed with DCM, and dried under vacuum to give 46 (1.09
g, 3.65 mmol, 93% yield). 1H NMR (DMSO-d6): δ 11.54 (bs, 1H),
9.27−9.25 (m, 1H), 8.60−8.57 (m, 1H), 8.01−7.99 (m, 1H), 3.95 (s,
3H); m/z 283.0. 285.0 [M + H]+.
Methyl 5-Bromo-8-(tosyloxy)-1,6-naphthyridine-7-carboxy-
late (49). To a suspension of 48 (1.3 g, 4.59 mmol) in DCM (31 mL),
triethylamine (0.96 mL, 6.89 mmol) and tosyl chloride (1.05 g, 5.51
mmol) were added, and the suspension was heated at 40 °C for 2 days.
A saturated solution of NaHCO3 (50 mL) was added, and the layers
were separated. The organic layer was dried over Na2SO4, filtered,
concentrated, and purified by flash chromatography (0−80% EtOAc/
cyclohexane) to give 49 (0.98 g, 2.3 mmol, 49%). 1H NMR (DMSO-
d6): δ 8.95−8.92 (m, 1H), 8.55−8.53 (m, 1H), 7.84−7.81 (m, 1H),
7.61 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 3.67 (s, 3H), 2.32 (s,
3H); m/z 437.0, 439.0 [M + H]+.
8-Hydroxy-5-(2-methoxyphenyl)-1,6-naphthyridine-7-car-
boxylic Acid (50). To a suspension of 49 (19.75 g, 45.2 mmol) in 1,4-
dioxane (339 mL) were added (2-methoxyphenyl)boronic acid (13.73
g, 90mmol), aqueous sodium carbonate (14.36 g, 136mmol, 113mL of
water), and tetrakis(triphenylphosphine)palladium(0) (2.61 g, 2.26
mmol), purged with N2, and stirred at 60 °C for 18 h. After cooling, the
mixture was partitioned between DCM (200 mL) and water (1.2 L),
and the organic phase was dried over Na2SO4, filtered, and
concentrated. The crude intermediate was purified by flash
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chromatography (0−100% EtOAc/ethanol (5:1)/cyclohexane) to give
methyl 5-(2-methoxyphenyl)-8-(tosyloxy)-1,6-naphthyridine-7-car-
boxylate (16 g, 34.5 mmol), which was used without further
purification. To a solution of the crude material (16 g, 34.5 mmol) in
DMF (34.4 mL) was added sodium methoxide in MeOH (172 mL, 86
mmol, 0.5 N), stirred at 50 °C for 5 min, cooled to RT, and stirred for a
further 15 min. Acetic acid (3.94 mL, 68.9 mmol)/water (130 mL) was
added, stirred for 30 min, and the resulting solid was collected and
washed with 1:1 MeOH/H2O (2 × 50 mL). The crude solid was taken
up in THF (193 mL)/MeOH (97 mL), a solution of lithium hydroxide
monohydrate (2.43 g, 58.0 mmol) in water (50mL) was added, and the
resulting suspension was stirred at 60 °C overnight. After cooling, pH
was adjusted to approximately 4−5 by addition of 2 M HCl, and the
resulting solid was collected, washed with 1:1 MTBE/cyclohexane, and
dried to give 50 (7.65 g, 26 mmol, 89%). 1H NMR (DMSO-d6): δ
8.99−8.97 (m, 1H), 7.79−7.76 (m, 1H), 7.57−7.54 (m, 1H), 7.52−
7.47 (m, 1H), 7.34−7.32 (m, 1H), 7.18−7.15 (m, 1H), 7.13−7.08 (m,
1H), 3.64 (s, 3H).
5-Bromo-N-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-
7-carboxamide (51a). 51a was synthesized by an analogous method
to 51b from 48 (120mg, 0.40mmol) and 4-chlorobenzylamine (57mg,
9.40 mmol) to give 51a (75 mg, 0.18 mmol, 45%). 1H NMR (DMSO-
d6): δ 13.70 (bs, 1H), 9.75 (bs, 1H), 9.24−9.21 (m, 1H), 8.59−8.57 (m,
1H), 7.97−7.94 (m, 1H), 7.42−7.41 (m, 4H), 4.56 (d, J = 6.4 Hz, 2H);
m/z 391.8, 393.8 [M + H]+.
5-Bromo-8-hydroxy-N-methyl-1,6-naphthyridine-7-carbox-
amide (51b). To 48 (1.3 g, 4.6 mmol) in EtOH (25 mL) was added
methylamine (33% in EtOH, 2.2 mL, 23 mmol) and stirred at 100 °C
overnight. The hot mixture was poured into water (40 mL)/acetic acid
(10 mL), allowed to cool to RT, stirred for 1 h, and the resulting solid
was collected, washed with water, and dried under vacuum to give 51b
(1.18 g, 3.96 mmol, 86% yield). 1H NMR (DMSO-d6): δ 13.98 (bs,
1H), 9.24−9.06 (m, 2H), 8.59−8.55 (m, 1H), 7.96−7.92 (m, 1H), 2.90
(d, J = 2.9 Hz, 3H); m/z 282.0, 284.0 [M + H]+.
5-Bromo-N-(cyclopropylmethyl)-8-hydroxy-1,6-naphthyri-
dine-7-carboxamide (51c). 51c was synthesized by an analogous
method to 51b from 48 (400 mg, 1.4 mmol) and cyclopropylmethan-
amine (150 mg, 2.1 mmol) to give 51c (392 mg, 1.16 mmol, 82%). 1H
NMR (DMSO-d6): δ 14.00 (bs, 1H), 9.28−9.22 (m, 2H), 8.62−8.58
(m, 1H), 8.00−7.95 (m, 1H), 3.26−3.23 (m, 2H), 1.18−1.12 (m, 1H),
0.51−0.45 (m, 2H), 0.34−0.30 (m, 2H); m/z 322.0 [M + H]+.
Intramacrophage L. donovani Assay. This assay was conducted
as previously described,8 except for compound exposure time, which
was 96 h instead of 72 h.
Kinetic Aqueous Solubility Assessment and Intrinsic Clear-
ance Experiments. These assays were conducted as previously
described.23
Chrom Log DpH7.4. This assay was conducted as previously
described.11
In vivoMouse Efficacy Studies. In vivo studies were carried out as
previously described.12
Ethical Statements. Mouse and Rat Pharmacokinetics. All
animal studies were ethically reviewed and carried out in accordance
with Animals (Scientific Procedures) Act 1986 and the GSK/Dundee
University Policy on the Care, Welfare, and Treatment of Animals.
In Vivo Efficacy. All regulated procedures, at the University of
Dundee, on living animals were carried out under the authority of a
project license issued by the HomeOffice under the Animals (Scientific
Procedures) Act 1986, as amended in 2012 (and in compliance with EU
Directive EU/2010/63). License applications will have been approved
by the University’s Ethical Review Committee (ERC) before
submission to the Home Office. The ERC has a general remit to
develop and oversee policy on all aspects of the use of animals on
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